Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cns Pharmaceuticals Inc (CNSP)
Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,779
  • Shares Outstanding, K 6,215
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,270 K
  • 60-Month Beta 2.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CNSP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.71
  • Most Recent Earnings $-1.08 on 11/14/23
  • Latest Earnings Date 04/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +333,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2290 +22.27%
on 01/31/24
0.6161 -54.55%
on 01/23/24
-0.3552 (-55.92%)
since 01/22/24
3-Month
0.2290 +22.27%
on 01/31/24
2.4200 -88.43%
on 11/24/23
-1.9700 (-87.56%)
since 11/22/23
52-Week
0.2290 +22.27%
on 01/31/24
4.4000 -93.64%
on 04/17/23
-1.3520 (-82.84%)
since 02/22/23

Most Recent Stories

More News
CNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced...

CNSP : 0.2796 (-2.34%)
CNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed...

CNSP : 0.2796 (-2.34%)
CNS Pharmaceuticals (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced...

CNSP : 0.2796 (-2.34%)
CNS Pharmaceuticals’ (NASDAQ: CNSP) Interim Analysis on Berubicin Trial Showing Promising Results

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. In September, the...

CNSP : 0.2796 (-2.34%)
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced...

CNSP : 0.2796 (-2.34%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today...

CNSP : 0.2796 (-2.34%)
CNS Pharmaceuticals (NASDAQ: CNSP) Releases Q3 2023 Results, Update on Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting...

CNSP : 0.2796 (-2.34%)
CNS Pharmaceuticals (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced rapid enrollment in its potentially pivotal study involving its flagship drug candidate, Berubicin, and is moving closer to reporting the results of...

CNSP : 0.2796 (-2.34%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate at Virtual Investor Ask the CEO Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured...

CNSP : 0.2796 (-2.34%)
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0276 (+2.22%)
GRI : 0.8500 (-11.46%)
MBRX : 0.5000 (-0.24%)
XBIO : 3.55 (-6.08%)
AREC : 1.3000 (-0.76%)
CNSP : 0.2796 (-2.34%)
NVNO : 5.65 (+6.20%)
PALI : 0.4275 (-0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

3rd Resistance Point 0.3230
2nd Resistance Point 0.3108
1st Resistance Point 0.2985
Last Price 0.2796
1st Support Level 0.2740
2nd Support Level 0.2618
3rd Support Level 0.2495

See More

52-Week High 4.4000
Fibonacci 61.8% 2.8067
Fibonacci 50% 2.3145
Fibonacci 38.2% 1.8223
Last Price 0.2796
52-Week Low 0.2290

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar